Craig Wylie is a Managing Partner at Arthur D. Little (ADL), based in Boston; and a member of ADL's global Healthcare & Life Sciences practice. His expertise is in the regulated functions of the life sciences industry, in particular, post-merger integration, R&D strategy and operations, inspection readiness, and findings remediation. Mr. Wylie's background is in R&D and quality operations, and he strongly believes that effective management of functions such as quality, regulatory, medical, and safety should be an enabler of value within the organization, not a burden, and that executed effectively these functions guide thinking without stifling innovation. He currently focuses on the effective implementation of quality and regulatory compliance within the highly regulated pharmaceutical environment. Mr. Wylie has worked with many of the world's largest pharmaceutical firms, including work on remediation of warning letters and consent decrees. Previously, he was a Partner at PA Consulting in the UK and the US, where he led the US team. Mr. Wylie holds a bachelor of science degree in computing science and management science from Stirling University. He can be reached at firstname.lastname@example.org.